A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy.

[1]  J. Griffiths,et al.  Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells. , 1998, British Journal of Cancer.

[2]  J. Griffiths,et al.  The effect of blood flow modification on intra- and extracellular pH measured by 31P magnetic resonance spectroscopy in murine tumours. , 1995, British Journal of Cancer.

[3]  G. Milano,et al.  Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review). , 1994, Anticancer research.

[4]  M. Slevin,et al.  Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. , 1994, British Journal of Cancer.

[5]  K. Jeong,et al.  Metabolic consequences of a reversed pH gradient in rat tumors. , 1994, Cancer research.

[6]  M O Leach,et al.  In vivo monitoring of fluoropyrimidine metabolites: magnetic resonance spectroscopy in the evaluation of 5-fluorouracil. , 1994, Anti-cancer drugs.

[7]  C. Presant,et al.  Association of intratumoral pharmacokinetics of fluorouracil with clinical response , 1994, The Lancet.

[8]  V. R. McCready,et al.  The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-α using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: A pilot study , 1993 .

[9]  S. Steinberg,et al.  Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a. , 1992, Journal of the National Cancer Institute.

[10]  Joseph,et al.  Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. , 1992, Cancer research.

[11]  J. Griffiths,et al.  Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarcoma following methotrexate pre-treatment: a 19F-MRS study in vivo. , 1992, British Journal of Cancer.

[12]  S. Wadler,et al.  Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells. , 1992, Biochemical and biophysical research communications.

[13]  J. Griffiths,et al.  Detection of differential sensitivity to 5‐fluorouracil in ehrlich ascites tumour cells by 19F NMR spectroscopy , 1991, NMR in biomedicine.

[14]  A. Croisy,et al.  pH dependence of 5-fluorouracil uptake observed by in vivo 31P and 19F nuclear magnetic resonance spectroscopy. , 1991, Cancer research.

[15]  J. Griffiths.  Are cancer cells acidic? , 1991, British Journal of Cancer.

[16]  R. Friedman,et al.  Primary amines enhance the antiviral activity of interferon against a membrane virus: role of intracellular pH. , 1991, The Journal of general virology.

[17]  J. Koutcher,et al.  Regulation of pH in murine tumor and muscle. , 1991, Radiation research.

[18]  J. Koutcher,et al.  In vivo monitoring of changes in 5‐fluorouracil metabolism induced by methotrexate measured by 19F NMR spectroscopy , 1991, Magnetic resonance in medicine.

[19]  T. Ng,et al.  19F magnetic resonance spectroscopy studies of the metabolism of 5-fluorouracil in murine RIF-1 tumors and liver. , 1991, Cancer research.

[20]  C. Presant,et al.  Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Allegra,et al.  Interaction of γ Interferon and 5-Fluorouracil in the H630 Human Colon Carcinoma Cell Line , 1990 .

[22]  J. H. Parish,et al.  Effect of 5-fluorouracil combination therapy on RNA processing in human colonic carcinoma cells. , 1990, British Journal of Cancer.

[23]  J. Griffiths,et al.  19F MRS studies of fluoropyrimidine chemotherapy. A review , 1989, NMR in biomedicine.

[24]  J. M. Sandoval,et al.  Interferon effects upon fluorouracil metabolism by HL-60 cells. , 1989, Biochemical and biophysical research communications.

[25]  J. Griffiths,et al.  Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo. , 1989, British Journal of Cancer.

[26]  J. Abita,et al.  An increase in intracellular pH is a general response of promonocytic cells to differentiating agents , 1988, FEBS letters.

[27]  R. Martino,et al.  Direct 19f NMR spectroscopic observation of 5‐fluorouracil metabolism in the isolated perfused mouse liver model , 1988, NMR in Biomedicine.

[28]  M. Calalb,et al.  Recombinant murine interferon-gamma-induced differentiation of pre-B lymphocytes is associated with Na+/H+ exchange-dependent and -independent cytoplasmic alkalinization. , 1988, The Journal of biological chemistry.

[29]  Enrico,et al.  31P-nuclear magnetic resonance analysis of interferon-induced alterations of phospholipid metabolites in interferon-sensitive and interferon-resistant Friend leukemia cell tumors in mice. , 1986, Cancer research.

[30]  F N Naguib,et al.  Enzymes of uracil catabolism in normal and neoplastic human tissues. , 1985, Cancer research.

[31]  J. Griffiths,et al.  5-fluorouracil metabolism monitored in vivo by 19F NMR. , 1984, British Journal of Cancer.

[32]  A Johnston,et al.  STRIPE: an interactive computer program for the analysis of drug pharmacokinetics. , 1983, Journal of pharmacological methods.

[33]  R G Shulman,et al.  Cerebral metabolic studies in vivo by 31P NMR. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Yin,et al.  Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. Collins,et al.  Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without interferon-alpha. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  C. Morton,et al.  Potentiation of 5-fluorouracil-leucovorin activity by alpha2a-interferon in colon adenocarcinoma xenografts. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  C. Allegra,et al.  Preclinical and clinical aspects of biomodulation of 5-fluorouracil. , 1994, Cancer treatment reviews.

[38]  S. Wadler,et al.  Mechanisms by which interferon potentiates chemotherapy. , 1993, Cancer investigation.

[39]  T. Ng,et al.  Thymidine-modulated 5-fluorouracil metabolism in liver and RIF-1 tumors studied by 19F magnetic resonance spectroscopy. , 1992, Magnetic resonance imaging.